Presenter(s): Felipe Castillo, MD
Target Audience: This activity is designed for physicians, nurses, psychologists, social workers, physician assistants, pharmacists, interprofessional team, residents/fellows, medical students, other mental health clinicians. This activity is accredited for physicians, nurses, social workers, physician assistants, pharmacists, interprofessional team, and other health professionals.
Credit Designations Available: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Social Work CE Credit, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Webinar Description:
There are not enough treatment providers to meet the needs of our patients with OUD. Telemedicine can increase access to patients who require ongoing substance use disorder treatment. However, there are numerous regulatory, logistical, and other clinical questions, which are also rapidly changing, around implementing telemedicine delivery of medication treatment for OUD (tele-MOUD). In this presentation, we will: present evidence on tele-MOUD but focus most of the discussion on clinical considerations in using implementing telemedicine to deliver quality buprenorphine treatment.
Educational Objectives:
- Recognize key changes in federal regulations and guidance since the onset of COVID-19 and what they mean for telemedicine for OUD treatment.
- Describe the potential ways that telemedicine for OUD treatment can address current treatment needs while also discussing important clinical considerations in using telemedicine for OUD treatment, including specific patients’ characteristics, clinic practices, and local resources to consider.
- Review information on key regulatory/legal requirements and technology considerations important to use of telemedicine for OUD treatment.